1. Home
  2. XPEL vs ARDX Comparison

XPEL vs ARDX Comparison

Compare XPEL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPEL Inc.

XPEL

XPEL Inc.

HOLD

Current Price

$48.80

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.49

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPEL
ARDX
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
XPEL
ARDX
Price
$48.80
$5.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$56.00
$15.14
AVG Volume (30 Days)
231.3K
3.3M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
12.12
N/A
EPS
0.37
N/A
Revenue
$476,200,000.00
$2,607,000.00
Revenue This Year
$12.64
$37.75
Revenue Next Year
$11.98
$34.24
P/E Ratio
$129.46
N/A
Revenue Growth
13.27
N/A
52 Week Low
$31.26
$3.74
52 Week High
$55.91
$8.40

Technical Indicators

Market Signals
Indicator
XPEL
ARDX
Relative Strength Index (RSI) 65.26 40.40
Support Level $45.60 $5.46
Resistance Level $49.58 $6.29
Average True Range (ATR) 1.71 0.31
MACD 0.29 0.04
Stochastic Oscillator 95.24 8.59

Price Performance

Historical Comparison
XPEL
ARDX

About XPEL XPEL Inc.

XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: